SOPHARMA  AD (the “Company”) notifies that for October 2013 the Company recorded a decrease of sales revenues of 3% compared to the same period of 2012, including 5% decrease of domestic sales and 3% decrease of export sales.

During the past ten months Sopharma AD recorded a decrease of sales revenues of 1%, including 5% increase of domestic sales and 3% decrease of export sales compared to the same period of 2012.

SOPHARMA AD (the “Company”) hereby informs that from 31 October 2013 up to and including 6 November 2013 the Company bought 17 612 own shares representing 0.013% of the share capital of the Company, to the total value of 57 936.2 BGN on the Bulgarian Stock Exchange. The average price per share was 3.29 BGN.

The shares have been bought on the basis of decision No. 7 of the Annual General Meeting of Shareholders from 23 June 2010.

The total number of treasury shares after these transactions is 5 368 415, representing 4.07% of the share capital of the Company.

SOPHARMA AD (the “Company”) hereby informs that from 7 November 2013 up to and including 13 November 2013 the Company bought 23,436 own shares representing 0.018% of the share capital of the Company, to the total value of 79 264.03 BGN on the Bulgarian Stock Exchange. The average price per share was 3.38 BGN.

The shares have been bought on the basis of decision No. 7 of the Annual General Meeting of Shareholders from 23 June 2010.

The total number of treasury shares after these transactions is 5 391 581, representing 4.08% of the share capital of the Company.

SOPHARMA AD (the “Company”) hereby informs that from 14 November 2013 up to and including 20 November 2013 the Company bought 7 570 own shares representing 0.006% of the share capital of the Company, to the total value of 26 414.24 BGN on the Bulgarian Stock Exchange. The average price per share was 3.49 BGN.

The shares have been bought on the basis of decision No. 7 of the Annual General Meeting of Shareholders from 23 June 2010.

The total number of treasury shares after these transactions is 5 399 421, representing 4.09% of the share capital of the Company.

SOPHARMA AD (the “Company”) hereby informs that from 21 November 2013 up to and including 27 November 2013 the Company bought 10 019 own shares representing 0.0076% of the share capital of the Company, to the total value of 35 268.79  BGN on the Bulgarian Stock Exchange. The average price per share was 3.52 BGN.

The shares have been bought on the basis of decision No. 7 of the Annual General Meeting of Shareholders from 23 June 2010.

The total number of treasury shares after these transactions is 5 409 440, representing 4.10% of the share capital of the Company.

Sopharma AD (the “Company”) notifies that it has invested in the capital increase of its subsidiary Briz (Riga , Latvia ) in order to expand its presence on the markets of the three Baltic States and Belarus. The shares of Sopharma AD in the capital of the company after the increase reached 66.14% (previously 51%). The expansion of the presence on the market of the Republic of Belarus includes acquisition of a warehouse complex, implementation of an integrated information system as well as the acquisition of new pharmacies.

Sopharma AD (the “Company”) notifies that today, 9 December 2013, the Company received official confirmation from the Ministry of Economy and Energy that the project "Implementation of innovative products in the ampoule production of Sopharma AD" under Operational Program "Development of the Competitiveness of the Bulgarian Economy" 2007-2013 was ranked 5th on the list of largest companies. The project is included in the list of project proposals approved for funding under the above procedure, with a maximum grant financing of 3,000,000 BGN.

SOPHARMA AD (the “Company”) hereby informs that from 5 December 2013 up to and including 11 December 2013 the Company bought 9 796 own shares representing 0.007% of the share capital of the Company, to the total value of 35 659.97  BGN on the Bulgarian Stock Exchange. The average price per share was 3.64 BGN.

The shares have been bought on the basis of decision No. 7 of the Annual General Meeting of Shareholders from 23 June 2010.

The total number of treasury shares after these transactions is 5 432 858, representing 4.12% of the share capital of the Company.

SOPHARMA AD (the “Company”) hereby informs that from 12 December 2013 up to and including 18 December 2013 the Company bought 22 008 own shares representing 0.017% of the share capital of the Company, to the total value of 85 612.83  BGN on the Bulgarian Stock Exchange. The average price per share was 3.89 BGN.

The shares have been bought on the basis of decision No. 7 of the Annual General Meeting of Shareholders from 23 June 2010.

The total number of treasury shares after these transactions is 5 454 866, representing 4.13% of the share capital of the Company.

SOPHARMA AD hereby informs that from 29 January 2015 up to and including 4 February 2015 the Company bought 3 200 own shares representing 0.0024% of the share capital of the Company, at a total value of 11 534.90 BGN on the Bulgarian Stock Exchange, the average price per share was 3.605 BGN.

The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.

The total number of treasury shares after these transactions is 5 126 021, representing 3.88% of the share capital of the Company.